These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 27835059

  • 41. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
    Toyoda F, Tanaka Y, Ota A, Shimmura M, Kinoshita N, Takano H, Matsumoto T, Tsuji J, Kakehashi A.
    J Diabetes Res; 2014; 2014():672590. PubMed ID: 25215304
    [Abstract] [Full Text] [Related]

  • 42. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
    Asano T, Saito Y, Kawakami M, Yamada N, Fidarestat Clinical Pharmacology Study Group.
    J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
    [Abstract] [Full Text] [Related]

  • 43. Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study.
    El-Sayed S, Metwally K, El-Shanawani AA, Abdel-Aziz LM, El-Rashedy AA, Soliman MES, Quattrini L, Coviello V, la Motta C.
    Bioorg Med Chem Lett; 2017 Oct 15; 27(20):4760-4764. PubMed ID: 28935265
    [Abstract] [Full Text] [Related]

  • 44. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA, Borja NL.
    Pharmacotherapy; 2008 May 15; 28(5):646-55. PubMed ID: 18447661
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb 15; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Enhanced dissolution and skin permeation profiles of epalrestat with β-cyclodextrin derivatives using a cogrinding method.
    Furuishi T, Takahashi S, Ogawa N, Gunji M, Nagase H, Suzuki T, Endo T, Ueda H, Yonemochi E, Tomono K.
    Eur J Pharm Sci; 2017 Aug 30; 106():79-86. PubMed ID: 28546106
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs.
    Kasuya Y, Ito M, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T, Naruse K, Nakashima E, Kato K, Koh N, Hotta N.
    Diabetologia; 1999 Dec 30; 42(12):1404-9. PubMed ID: 10651257
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
    Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, Nakamura J, Oikawa S, Yamada N, Yasuda H, Shigeta Y, ADCT Study Group.
    Diabet Med; 2008 Jul 30; 25(7):818-25. PubMed ID: 18644069
    [Abstract] [Full Text] [Related]

  • 60. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
    Tsugawa T, Shinohara R, Nagasaka A, Nakano I, Takeda F, Nagata M, Oda N, Sawai Y, Hayakawa N, Suzuki A, Itoh M.
    J Endocrinol; 2004 Jun 30; 181(3):429-35. PubMed ID: 15171691
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.